

RESEARCH ARTICLE

Open Access



Effects of vitamin D deficiency on blood lipids and bone metabolism: a large cross-sectional study

Peng Gu^{1†}, Bin Pu^{1†}, BaiHang Chen¹, XiaoHui Zheng^{1,2}, ZhanPeng Zeng^{1,2} and WeiDong Luo^{1,2*}

Abstract

To investigate the relationship between serum high-density lipoprotein (HDL-C) and spinal bone mineral density (BMD) under different serum 25-hydroxyvitamin D (25 (OH) D) levels in adults over 40 years old and to explore its mechanism. We include participants over the age of 40 with data on HDL-C, 25 (OH) D, spinal BMD, and other variables in the National Health and Nutrition Examination Survey 2007–2010 in the analysis. A weighted multiple linear regression model was used to evaluate the association between serum HDL-C and spinal BMD in different gender, ages, and serum 25 (OH) D levels. A total of 3599 subjects aged ≥ 40 years old were included in this study. Univariate analysis of the complete correction model showed a negative correlation between serum HDL-C and spinal BMD. In the two subgroups of serum 25 (OH) D, we found that the higher the serum HDL-C in the female with serum 25 (OH) D < 75 nmol/L aged 40–59 years old, the lower the total spinal BMD, and a similar relationship was found in the lumbar spine. However, no similar relationship was found in all populations with serum 25 (OH) D ≥ 75 nmol/L and males with serum 25 (OH) D < 75 nmol/L. These results suggest that among Americans over the age of 40, the increase in serum HDL-C is related to decreased BMD of spine only in women aged 40–59 years with vitamin D insufficiency or deficiency.

Keywords Bone mineral density, 25-Hydroxyvitamin D, High-density lipoprotein cholesterol, Osteoporosis, NHANES

Introduction

Osteoporosis (OP) is a systemic skeletal disease common in the elderly, which is characterized by reduced bone mass per unit volume, decreased bone strength, destruction of bone microstructure and increased risk of fracture [1]. OP is often associated with brittle fractures, with approximately 1/2 of women and 1/5 of men expected to

experience an osteoporotic fracture during their lifetime [2]. Bone mineral density (BMD) is a standard parameter to evaluate bone health. There are many risk factors for BMD reduction, including genetic, lifestyle and nutrition factors, which have been identified to be related to BMD reduction [3–5]. The existing evidence also showed that abnormal blood lipid metabolism [6–8] and serum vitamin D deficiency [9, 10] were closely related to osteoporosis. Patients with hyperlipidemia can have bone loss and osteoporotic fracture simultaneously. Patients with OP and osteopenia are also often complicated with abnormal blood lipid metabolism [11], especially the abnormal metabolism of serum high-density lipoprotein (HDL-C) [12]. Serum vitamin D is an essential factor in regulating the balance of calcium, phosphorus and bone metabolism, and the appropriate nutritional status

[†]Peng Gu and Bin Pu contributed equally to this work

*Correspondence:

WeiDong Luo
65225202@qq.com

¹ Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

² The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China



of vitamin D is significant for the maintenance of bone health [13]. Vitamin D deficiency is associated with various diseases harmful to bone health, including diabetes, chronic obstructive pulmonary disease [14], a variety of autoimmune diseases [15] and dyslipidemia [16].

Existing studies indicated that serum HDL-C levels were negatively correlated with bone status in postmenopausal women with vitamin D deficiency [17]. However, this relationship was only evaluated in postmenopausal women and did not extend to all age groups and men, and it was a single-center clinical study with a small sample size. This study conducted a cross-sectional study combining data from two cycles (2007–2008 and 2009–2010) of the National Health and Nutrition Examination Survey (NHANES) to provide more evidence-based references further. It was objective for the study to evaluate the association between serum HDL-C and BMD at different serum vitamin D levels and to provide guidance for regulating serum vitamin D and HDL-C levels to reduce the risk of osteopenia or OP.

Methods

Data source and study design

NHANES is a series of continuous cross-sectional surveys conducted jointly by the National Center for Health Statistics (NCHS) and the Centers for Disease Control and Prevention (CDC) to include information about a representative general non-institutionalized population of all ages in the United States to assess their nutrition and health status. It is reviewed and approved by the NCHS Research Ethics Review Board and obtained all participants' written and informed consent. This survey includes two parts: interview and physical examination data. The interview part mainly collects demographic data, questionnaire data, and dietary data. The physical examination mainly includes massive laboratory data and examination data. Each individual in the database is replaced with a unique ID and does not include any personally identifiable private information.

This study combines the data of NHANES 2007–2010. Inclusion criteria included: (1) participants ≥ 40 years old, (2) participants with available spinal BMD, HDL-C, and 25 (OH) D data. Exclusion criteria included: (1) subjects who have been treated for osteoporosis (who have treated osteoporosis); (2) prednisone or cortisone every day (prednisone or cortisone tablets almost every day for a month or more?); (3) subjects with kidney weakness or failure (have you been told by your doctor or other health professionals that you have kidney weakness or failure? Does not include kidney stones, bladder infection or incontinence). (4) Subjects with missing data of other variables were excluded. Finally, among 20,686 participants, through strict eligibility criteria, a total of 3599




Fig. 1 Flowchart of participants selection

participants were included in the study (Fig. 1). Data collection/analysis for this study was conducted from January to March 2022. The date that participants were recruited to the study and the date range in which human subjects' data/samples visit <https://wwwn.cdc.gov/nchs/nhanes/Default.aspx>.

Measurement of serum 25 (OH) D level

For the two cycles of NHANES 2007–2010, 25-hydroxyvitamin D3 (25 (OH) D3), epi-25- hydroxyvitamin D3 (epi-25 (OH) D3) and 25-hydroxyvitamin D2 (25 (OH) D2) were determined by ultra-high-performance liquid chromatography-tandem mass spectrometry. Total 25 (OH) D is the sum of 25 (OH) D2 and 25 (OH) D3 but does not include epi-25 (OH) D3. Detailed instructions on specimen collection and processing can be found on the NHANES. Websites (https://wwwn.cdc.gov/nchs/nhanes/2007-2008/VID_E.htm and https://wwwn.cdc.gov/nchs/nhanes/2009-2010/VID_F.htm). According to the guidelines for the evaluation, treatment, and prevention of vitamin D deficiency issued by the American Endocrine Association in July 2014, 25 (OH) D levels were divided into two groups: serum vitamin D insufficiency or deficiency group with total 25 (OH) D concentration < 75 nmol/L and serum vitamin D normal group with total 25 (OH) D concentration ≥ 75 nmol/L [18].

Measurement of serum HDL-C level

Subjects' sera were collected to measure HDL-C levels and all samples were analyzed at the University of Minnesota Lipid Laboratory using a Roche modular P chemical analyzer. Magnesium sulfate/glucose solution, cholesterol oxidase and polyethylene glycol coupled cholesterol esterase and other reagents were used for determination. These reagents are related to a laboratory method reference material in the cholesterol reference method laboratory network certified by the CDC Lipid Standardization Program, with no differences in the generation assays between measurements.

Measurement of results and covariates

The outcome variables are the spinal BMD (total spinal BMD, L1-L4BMD) measured by dual-energy X-ray absorptiometry on the Hologic Discovery model A densitometer (Hologic, Inc., Bedford, Massachusetts). All scans were analyzed using Hologic APEX3.0 software. Covariates include demographic data, such as age, gender, race, education level, marital status, body mass index (BMI, kg/m²), C-reactive protein (CRP, mmol/L), serum total calcium concentration (Ca, mmol/L), phosphorus (P, mmol/L), total cholesterol (TC, mmol/L), alkaline phosphatase (ALP, U/L), aspartate aminotransferase (AST, U/L), alanine aminotransferase (ALT, U/L), smoking status, alcohol consumption, hypertension, diabetes. Covariates were collected through family interviews, physical examination, laboratory measurements, and questionnaires. For more details on data collection, visit <https://wwwn.cdc.gov/nchs/nhanes/ContinuousNhanes/Default.aspx?BeginYear=2007> and <https://wwwn.cdc.gov/nchs/nhanes/ContinuousNhanes/Default.aspx?BeginYear=2009>.

Statistical analysis

To account for oversampling in complex survey design, survey nonresponse, and poststratification, the 2007/2008 and 2009/2010 cycles were combined, and 4-y sampling weights were constructed by using one-two of the 2-y sampling weight (WTMEC2YR) constructed by the NHANES. The baseline characteristics of all study participants were described by average (continuous variables) or proportions (classified variables). Weighted multiple linear regression model evaluated the linear relationship between serum HDL-C and BMD. Unadjusted and multivariate-adjusted logical regression analyses were used to calculate the P value and the corresponding 95% confidence interval (CI) to determine the relationship between serum HDL-C levels and spinal BMD. The coarse model was adjusted to no variable. The multivariate model included age, sex, race, smoking status, alcohol consumption, hypertension, diabetes, BMI,

CRP, Ca, P, TC, ALP, AST, ALT. We selected these confounding factors based on their association with more than 10% changes in the estimated results or effects of interest. Multiple linear regression models were used for subgroup analysis, and the linear relationship between serum HDL-C and spinal BMD in different populations was evaluated by sex, age, and serum 25 (OH) D stratification. $P < 0.05$ is defined as significant. Multi-factor histogram was used to describe the independent association between BMD and HDL-C in different parts of a specific population. All analyses were conducted using R (version 4.0.3) and EmpowerStats software (<http://www.empowerstats.com>). The figures were generated using GraphPad Prism 9.0.0(121) (<https://www.graphpad.com/>).

Results

Participant selection and baseline characteristics

Participants' information was extracted from the NHANES database 2007–2010. (i) exclusion of subjects younger than 40 ($n=12,526$), (ii) exclusion of subjects without spinal BMD data ($n=3338$), (iii) exclusion of subjects without HDL-C, 25 (OH) D data ($n=488$) (iv) excluding subjects who had treated osteoporosis, used or continued hormone therapy, and suffered from kidney weakness or failure ($n=524$) (v) excluded the missing values of other variables ($n=211$). After that, 3599 participants (Fig. 1) participated in the final analysis.

Table 1 shows the description of weighted sociodemographic and medical characteristics of the participants, including 1814 males and 1785 females, with an average age of 54.09 ± 10.33 years for males and 54.11 ± 10.44 years for females. The baseline characteristics of the selected participants were compared between different gender groups. Compared with male participants, female participants had higher levels of 25(OH)D (70.99 ± 27.31), HDL-C (1.55 ± 0.45) and lower total lumbar BMD (1.00 ± 0.14). In addition, female participants tend to be thinner, lived alone more, smoked currently more, drank less, had higher serum phosphorus, CRP, ALP, TC, lower ALT, AST (all $P < 0.05$), and other related covariates had no significant difference (all $P > 0.05$).

Relationship between serum HDL-C and BMD

Serum HDL-C was negatively correlated with BMD, model 1 (without adjusting covariates). After adjusting for confounding factors, model 2 (age, sex, race/ethnicity were adjusted), and model 3 (all covariates were adjusted), all have similar results. There were significant differences in trend test results between the two groups ($P < 0.05$) (Table 2).

Table 1 Characteristics of study sample: US population aged ≥ 40 years in the NHANES 2007–2010

Characteristics	Total number of participants (n = 3599)		P
	Men (n = 1814)	Women (n = 1785)	
Age (years, mean \pm SD)	54.09 \pm 10.33	54.11 \pm 10.44	0.9449
Race/ethnicity, n (%)			0.6246
Mexican American	338 (7.32)%	362 (7.08)%	
Other Hispanic	194 (3.99)%	201 (4.02)%	
Non-Hispanic White	893 (74.64)%	848 (74.27)%	
Non-Hispanic Black	321 (8.78)%	317 (10.07)%	
Other race	68 (5.27)%	57 (4.56)%	
Education, n (%)			0.3241
Under high school	561 (18.27)%	533 (17.47)%	
High school or equivalent	415 (23.26)%	403 (23.57)%	
Some college or AA degree	427 (26.88)%	484 (29.35)%	
College graduate or above	411 (31.59)%	365 (29.61)%	
BMI, mean \pm SD (kg/m ²)	28.53 \pm 4.70	28.12 \pm 6.26	0.0286
Smoking, n (%)			<0.0001
Never	441 (22.96)%	318 (18.19)%	
Former	584 (29.19)%	381 (22.90)%	
Current	789 (47.84)%	1086 (58.92)%	
Had at least 12 alcohol drinks past one year? n (%)			<0.0001
Yes	1501 (85.03)%	1058 (67.82)%	
No	313 (14.97)%	727 (32.18)%	
Marital status			<0.0001
Live with someone	1327 (77.20)%	1043 (66.13)%	
Live alone	487 (22.80)%	742 (33.87)%	
Hypertension, n (%)			0.1586
Yes	714 (35.98)%	715 (33.74)%	
No	1100 (64.02)%	1070 (66.26)%	
Diabetes, n (%)			0.2750
Yes	254 (10.23)%	247 (8.69)%	
No	1521 (87.97)%	1505 (89.61)%	
Borderline	39 (1.79)%	33 (1.70)%	
Total 25 (OH) D (nmol/l)	67.04 \pm 22.53	70.99 \pm 27.31	<0.0001
Phosphorus (mmol/L, mean \pm SD)	1.16 \pm 0.18	1.25 \pm 0.17	<0.0001
Total calcium (mmol/L, mean \pm SD)	2.35 \pm 0.09	2.36 \pm 0.09	0.1269
CRP (mmol/L, mean \pm SD)	0.28 \pm 0.59	0.41 \pm 0.76	<0.0001
HDL-C (mmol/L, mean \pm SD)	1.24 \pm 0.38	1.55 \pm 0.45	<0.0001
TC (mmol/L, mean \pm SD)	5.19 \pm 1.09	5.39 \pm 1.04	<0.0001
ALP (U/L, mean \pm SD)	66.98 \pm 20.58	68.47 \pm 22.09	0.0359
ALT (U/L, mean \pm SD)	30.77 \pm 25.05	22.24 \pm 13.05	<0.0001
AST (U/L, mean \pm SD)	28.49 \pm 16.87	24.51 \pm 11.28	<0.0001
Total spine BMD (g/cm ² , mean \pm SD)	1.06 \pm 0.15	1.00 \pm 0.14	<0.0001
L1 BMD (g/cm ² , mean \pm SD)	1.00 \pm 0.14	0.90 \pm 0.15	<0.0001
L2 BMD (g/cm ² , mean \pm SD)	1.07 \pm 0.15	1.00 \pm 0.15	<0.0001
L3 BMD (g/cm ² , mean \pm SD)	1.08 \pm 0.16	1.04 \pm 0.15	<0.0001
L4 BMD (g/cm ² , mean \pm SD)	1.08 \pm 0.16	1.04 \pm 0.15	<0.0001

NHANES—National Health and Nutrition Examination Survey; SD—Standard deviation; Values are mean \pm SD or n (%). HDL-C—High-density lipoprotein cholesterol; BMI—Body mass index; CRP—C-reactive protein; TC—Cholesterol; ALP—Alkaline phosphatase; ALT—Alanine aminotransferase; AST—Aspartate aminotransferase; BMD—Bone mineral density; CI—Confidence interval; β —Regression coefficient

Table 2 Correlation between high-density lipoprotein-cholesterol and bone mineral density

BMD	Model 1		Model 2		Model 3	
	β (95% CI)	P	β (95% CI)	P	β (95% CI)	P
Total spine	-0.055 (-0.066, -0.044)	<0.00001	-0.043 (-0.054, -0.032)	<0.00001	-0.018 (-0.031, -0.006)	0.00373
L1	-0.082 (-0.093, -0.071)	<0.00001	-0.053 (-0.064, -0.042)	<0.00001	-0.026 (-0.038, -0.013)	0.00005
L2	-0.062 (-0.073, -0.050)	<0.00001	-0.045 (-0.056, -0.033)	<0.00001	-0.021 (-0.034, -0.008)	0.00133
L3	-0.044 (-0.055, -0.032)	<0.00001	-0.041 (-0.053, -0.028)	<0.00001	-0.016 (-0.029, -0.002)	0.02179
L4	-0.041 (-0.053, -0.030)	<0.00001	-0.037 (-0.049, -0.025)	<0.00001	-0.014 (-0.027, -0.000)	0.04453

Model 1, no covariates were adjusted

Model 2, age, sex, race/ethnicity, were adjusted

Model 3, age, sex, race/ethnicity, Education, Smoking, Had at least 12 alcohol drinks past one year?, Marital status, Hypertension, Diabetes, Total 25 (OH) D, BMI (obese, overweight, normal), TC (quartile groups), Ca (quartile groups), P (quartile groups), ALP (quartile groups), ALT (quartile groups), AST (quartile groups), CRP (quartile groups) were adjusted in the model

Relationship between serum HDL-C and BMD at different levels of serum 25 (OH) D

In all covariant adjusted models, we observed that when serum 25 (OH) D < 75 nmol/l, serum HDL-C was negatively correlated with total spine and L1-L4 BMD (P < 0.05). However, when serum 25 (OH) D ≥ 75 nmol/l, there was no correlation between serum HDL-C and total spine and L1-L4 BMD (P > 0.05) (Table 3).

Furthermore, the subgroup analysis of people with serum 25 (OH) D < 75 nmol/l by sex and age showed that when serum 25 (OH) D < 75 nmol/l, there were differences in the association between serum HDL-C level and BMD in different sex and age groups. When serum 25 (OH) D < 75 nmol/l, the spine BMD (total spine and L1-L4) of men of all ages were not correlated with HDL-C (P > 0.05). The total spine, L1 and L4 BMD of female of 40 ≤ aged < 60, the L2 BMD of 40 ≤ Aged < 50 female and the L3 BMD of 50 ≤ Aged < 60 female were negatively correlated with serum HDL-C, while the L2 BMD of 50 ≤ Aged < 60 female, the L3 BMD of 40 ≤ Aged < 50 female and the remaining 60–80 age group did not correlate with serum HDL-C (Table 4). Classification of Women aged 40–59 years with serum

25 (OH) D < 75 nmol/l into low, middle and high groups based on the third quartile interval of serum HDL-C concentration, the results were a negative correlation between different serum HDL-C groups and BMD, and the association between BMD in different lumbar vertebrae was L1 < L2 < L3 < L4 (Additional file 1: Fig. 1).

Relationship between serum HDL-C and BMD based on horizontal stratification of covariates

After stratified analysis of the relationship between serum HDL-C and spinal BMD by using all covariates (the covariates with continuous data as classified variables) as line stratified variables, it was found that the serum HDL-C of non-Hispanic blacks, people living with someone, smokers, people with education below high school level and people with highest ALP quartile had a negative correlation with spinal BMD (Additional file 2: Table 1).

Discussion

This study investigated the association between serum HDL-C and spinal BMD at different serum 25 (OH) D levels among Americans over 40 years old in a nationally representative sample. After adjusting all covariates,

Table 3 Correlation between high-density lipoprotein cholesterol and bone mineral density based on 25 (OH) D status classification

BMD	Total 25 (OH) < 75 (nmol/l) (n = 2565)		Total 25 (OH) ≥ 75 (nmol/l) (n = 1034)	
	Adjust β (95% CI)	P	Adjust β (95% CI)	P
Total spine	-0.024 (-0.040, -0.008)	0.0033	-0.007 (-0.028, 0.014)	0.5062
L1	-0.032 (-0.048, -0.016)	<0.0001	-0.013 (-0.033, 0.008)	0.2315
L2	-0.025 (-0.042, -0.009)	0.0025	-0.010 (-0.032, 0.012)	0.3622
L3	-0.020 (-0.037, -0.002)	0.0289	-0.008 (-0.031, 0.015)	0.4913
L4	-0.022 (-0.039, -0.005)	0.0131	-0.000 (-0.023, 0.023)	0.9929

Age, sex, race/ethnicity, Education, Smoking, Had at least 12 alcohol drinks past one year? Marital status, Hypertension, Diabetes, BMI (obese, overweight, normal), TC (quartile groups), Ca (quartile groups), P (quartile groups), ALP (quartile groups), ALT (quartile groups), AST (quartile groups), CRP (quartile groups) were adjusted in the model

Table 4 Correlation between high-density lipoprotein cholesterol and bone mineral density based on gender and age status classification

BMD	Age	Male (n = 1341)		Female (n = 1224)	
		Adjust β (95% CI)	P	Adjust β (95% CI)	P
Total spine	40 \leq Aged < 50	-0.007 (-0.048, 0.034)	0.7390	-0.038 (-0.068, -0.007)	0.0161
	50 \leq Aged < 60	-0.024 (-0.074, 0.026)	0.3507	-0.053 (-0.097, -0.010)	0.0176
	60 \leq Aged < 70	0.008 (-0.045, 0.060)	0.7749	-0.015 (-0.060, 0.031)	0.5271
	70 \leq Aged	-0.006 (-0.076, 0.065)	0.8730	-0.028 (-0.108, 0.052)	0.4989
L1	40 \leq Aged < 50	-0.003 (-0.045, 0.039)	0.8824	-0.056 (-0.089, -0.024)	0.0007
	50 \leq Aged < 60	-0.036 (-0.085, 0.013)	0.1538	-0.063 (-0.110, -0.017)	0.0076
	60 \leq Aged < 70	-0.017 (-0.068, 0.034)	0.5142	-0.036 (-0.078, 0.006)	0.0984
	70 \leq Aged	-0.004 (-0.070, 0.062)	0.9061	-0.041 (-0.116, 0.034)	0.2909
L2	40 \leq Aged < 50	-0.016 (-0.058, 0.026)	0.4512	-0.033 (-0.066, -0.001)	0.0448
	50 \leq Aged < 60	-0.032 (-0.083, 0.019)	0.2233	-0.042 (-0.088, 0.005)	0.0786
	60 \leq Aged < 70	0.021 (-0.032, 0.074)	0.4453	-0.016 (-0.063, 0.030)	0.4904
	70 \leq Aged	-0.013 (-0.085, 0.059)	0.7291	-0.052 (-0.130, 0.027)	0.1994
L3	40 \leq Aged < 50	0.005 (-0.040, 0.050)	0.8314	-0.027 (-0.060, 0.007)	0.1185
	50 \leq Aged < 60	-0.006 (-0.060, 0.049)	0.8375	-0.059 (-0.107, -0.012)	0.0144
	60 \leq Aged < 70	0.020 (-0.038, 0.079)	0.4962	-0.013 (-0.064, 0.039)	0.6255
	70 \leq Aged	-0.013 (-0.089, 0.063)	0.7417	-0.036 (-0.124, 0.053)	0.4286
L4	40 \leq Aged < 50	-0.014 (-0.058, 0.030)	0.5257	-0.037 (-0.070, -0.005)	0.0229
	50 \leq Aged < 60	-0.028 (-0.083, 0.027)	0.3198	-0.048 (-0.094, -0.003)	0.0396
	60 \leq Aged < 70	0.005 (-0.054, 0.063)	0.8727	-0.002 (-0.054, 0.049)	0.9323
	70 \leq Aged	0.005 (-0.076, 0.086)	0.9081	0.004 (-0.084, 0.092)	0.9277

Race/ethnicity, Education, Smoking, Had at least 12 alcohol drinks past one year?, Marital status, Hypertension, Diabetes, Total 25 (OH) D, BMI (obese, overweight, normal), TC (quartile groups), Ca (quartile groups), P (quartile groups), ALP (quartile groups), ALT (quartile groups), AST (quartile groups), CRP (quartile groups) were adjusted in the model

the weighted multiple linear regression model analysis showed a significant negative correlation between serum HDL-C and spinal BMD in women aged 40–59 years with serum 25 (OH) D < 75 nmol/L.

Some studies have found an inverse relationship between blood lipid levels and bone mass. For example, (1) adipocytes in lipid metabolism and osteoblasts in osteocytes are differentiated from Mesenchymal Stem Cells (MSCs) [19]; a long-term high-fat diet promotes MSCs to differentiate into adipocytes rather than osteoblasts, thus inhibiting bone formation. (2) High-fat environment promotes the transformation of osteoblasts into adipocytes in bone marrow [20]. (3) High-fat environment enhances the bone resorption function of osteoclasts by increasing the levels of Type I collagen carboxy-terminal peptide (CTX-1) and Thrombospondin Related Adhesive Protein (TRAP) [21]. (4) High-fat environment causes massive blood lipids and lipoproteins deposition in the arterial wall and the matrix of the subendothelial layer of bone vessels, resulting in lipid peroxidation. Lipid peroxides accelerated the inflammatory reaction of the arterial wall and inhibited the differentiation and bone mineralization of osteocytes [22].

This significant relationship is indistinguishable and includes all the components tested in the blood fat spectrum: TC, HDL-C, Low-density lipoprotein cholesterol (LDL-C) and Triglycerides (TG) [23]. However, few studies on the correlation and mechanism between increased HDL-C and decreased BMD. Kha et al. reported that specific oxysterol could stimulate MSCs to differentiate into osteoblasts, while high serum HDL-C level can remove oxysterol from peripheral tissue, which has a negative impact on osteogenic differentiation [24]. Dennison et al. found that serum high serum HDL-C level is related to higher fat content and higher body weight. There is a negative correlation between BMD and serum HDL-C in women, but the correlation decreases after adjusting the fat ratio [25]. Jirapinyo et al. observed that oral estrogen/progesterone combination increased BMD but decreased serum HDL-C levels in postmenopausal women [26]. Mazidi et al. found that serum HDL-C was positively correlated with inflammatory markers such as C-reactive protein, leukocyte and fibrinogen [27]. Therefore, it can be speculated that serum HDL-C and bone metabolism mechanisms may be related to hormone deficiency and inflammatory response.

In addition, the correlation between serum HDL-C and spinal BMD was different at separate serum 25 (OH) D levels. Serum HDL-C was a negative correlation with total spine and L1-L4 BMD at serum 25 (OH) D < 75 nmol/l ($P < 0.05$). However, when serum 25 (OH) D ≥ 75 nmol/l, there was no correlation between total spine, L1-L4 BMD and HDL-C ($P > 0.05$) (Table 3). One possible mechanism is that 1,25-(OH) 2D3 in serum 25 (OH) D can inhibit the secretion and mRNA expression of apolipoprotein AI (the main apolipoprotein of HDL-C), which makes the activity of apolipoprotein AI promoter decrease, affects the level and function of HDL-C [28–30], and then weakens the process of bone regeneration inhibition in the high-fat environment. Another possible mechanism is a positive correlation between serum 25 (OH) D and BMD [28, 31], which reduces or even eliminates the correlation between serum HDL-C and BMD. The molecular mechanism is that serum 25 (OH) D regulates calcium homeostasis by affecting intestinal calcium absorption, renal calcium reabsorption and osteoclast bone resorption [32]. Serum vitamin D can act on vitamin D response elements of osteoblasts and bone nuclei, and regulate the expression of osteocalcin, low-density lipoprotein receptor-related protein 5, fibroblast growth factor 23, type I collagen and other proteins, which has a substantial regulatory effect on bone turnover and bone mineralization [33].

To further explore the correlation between BMD and serum HDL-C and its possible mechanism in different populations with serum 25 (OH) D < 75 nmol/L, we carried out a stratified analysis of sex and age in all populations with serum 25 (OH) D < 75 nmol/L. The results showed that the correlation between serum HDL-C and BMD varies with gender and age when serum 25 (OH) D < 75 nmol/L. The negative correlation between serum HDL-C and BMD only exists in the female population, especially those 40–59 years. It is similar to previous studies that have shown that the serum HDL-C level in postmenopausal women with osteopenia or OP is higher [17, 34, 35]. There are several possible reasons for this difference. First, there are differences in the pathogenesis of osteoporosis between men and women. Hypercalciuria, abnormal testosterone metabolism level, hormone disorder related to bone metabolism and hypogonadism caused by aging are the leading causes of osteoporosis in older men [36], while estrogen deficiency caused by drastic changes of sex hormone levels in women aged 40–59 years may be the leading cause of OP in this age group [17, 37]. Estrogen deficiency can increase apoptosis of osteoblasts, which can act on the estrogen receptor α (ER α) target of osteoblasts to inhibit the differentiation of osteoblasts and increase apoptosis, and also impede the production

of receptor activator of nuclear factor- κ B (RANK) by osteoblasts, T cells and B cells, and reduce the activity of osteoblasts [38]. Estrogen deficiency in women before and after menopause will lead to a decrease in the level of osteoprotegerin (OPG), promote local bone inflammation and promote the expression of inflammatory cytokines. The increased expression of inflammatory factors can also enhance the activity of osteoclasts, which further leads to the aggravation of bone mass loss [39]. Estrogen deficiency breaks the balance between bone formation and bone resorption [40]. This process is not significant in elderly male. Secondly, studies have shown that changes in menopause can lead to depression. Depression may increase the risk of osteoporosis by stimulating glucocorticoid secretion and increasing pro-inflammatory cytokines [41]. In addition, tricyclic antidepressants in patients with depression may also have a negative effect on BMD [42]. Women's overall level of physical activity is lower than that of men [43]. The gender differences in bone size and geometry, bone histomorphometry and sex hormones may be the reasons for the difference in bone mass and degree of osteoporosis between men and women [44].

Most studies only confirmed a correlation between serum HDL-C and BMD [45–47]. Our results are more accurate and specific than the previous simple negative correlation between serum HDL-C and BMD. This was of great significance for clinicians and this population to closely observe BMD and early intervention to prevent OP. In addition, this study based on NHANES database data, the sample size is large, the clinical data are sufficient, and the study population based on the general population, which may be more representative than the population recruited from the hospital.

In this study, we also found that the β value and significance of the correlation between L1-L4 BMD with serum HDL-C decreased in turn (Table 2), which indicated that the L1 BMD is significantly affected by the increase in serum HDL-C level, and the correlation was the most significant, followed by L2, L3, L4. The comparison of L1-L4 BMD in the original data of the included population also found that the relationship between lumbar BMD size of all subjects in the population was L1 < L2 < L3 < L4 (Fig. 2). A reasonable explanation may be that the decrease in spinal BMD begins at L1 or L1 BMD is more affected by bone mass loss caused by various factors such as aging, and this relationship was also found in a census study of lumbar vertebrae BMD [48].

The limitations of the study are stated below:




Fig. 2 Classification of women aged 40–60 years with serum 25 (OH) D < 75 nmol/l based on the tertile interval of HDL-C concentration, and the association between different HDL-C groups and BMD

- Because of its cross-sectional design, this study cannot accurately detect the causal relationship between serum HDL-C, serum 25 (OH) D levels and BMD.
- Collecting questionnaire data through questionnaires and interviews may lead to recall bias and affect the study's conclusions.
- All the participants in this study are American residents, and the conclusions may not apply to all populations and races.

In general, more extensive data, rigorous experimental and multi-center designs are needed in future to verify further the conclusion that serum HDL-C is negatively correlated with BMD, as well as more fundamental studies on the molecular level of HDL-C and bone metabolism to obtain a relatively more objective and reliable evidence-based basis.

Conclusion

Our result showed a significant negative correlation between serum HDL-C and spinal BMD in women aged 40–59 years with serum 25 (OH) D < 75 nmol/L. Increased serum HDL-C during vitamin D deficiency is a potential risk factor for osteoporosis in middle-aged and elderly American women.

Abbreviations

BMD	Bone mineral density
HDL-C	High-density lipoprotein cholesterol
25 (OH) D	25-Hydroxyvitamin D
OP	Osteoporosis
NHANES	National Health and Nutrition Examination Survey
SD	Standard deviation
CRP	C-reactive protein

BMI	Body mass index
TC	Cholesterol
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
CI	Confidence interval

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13018-022-03491-w>.

Additional file 1. Figure S1. Bone mineral density of different lumbar vertebrae in participants.

Additional file 2. Table S1. Correlation between high-density lipoprotein cholesterol and bone mineral density based on covariate status classification.

Acknowledgments

None.

Author contributions

Conception and design were contributed by PG, BP, WL. Data collection was contributed by BC. Analysis and interpretation were contributed by PG, BP, XZ, ZZ, WL. Writing—review and editing was contributed by PG, BP, WL. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Some or all data generated or analyzed during this study are included in this published article or in the data repositories listed in References. NHANES data is available publicly at <https://www.cdc.gov/nchs/nhanes/Default.aspx>.

Declarations

Ethics approval and consent to participate

The original survey was approved by the NCHS Research Ethics Review Board and all adult participants provided written informed consent. The present analysis was deemed exempt by the Institutional Review Board at our institution, as the dataset used in the analysis was completely de-identified.

Competing interests

The authors declare that they have no competing interests and have not received Grant support or research funding.

Received: 28 June 2022 Accepted: 30 December 2022

Published online: 07 January 2023

References

1. Ukon Y, Makino T, Kodama J, Tsukazaki H, Tateiwa D, Yoshikawa H, et al. Molecular-based treatment strategies for osteoporosis: a literature review. *Int J Mol Sci.* 2019;20(10):2557. <https://doi.org/10.3390/ijms20102557>.
2. Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. *Clin Chem.* 2017;63(2):464–74. <https://doi.org/10.1373/clinchem.2016.259085>.
3. Cvijetic S, Colic BI, Satalic Z. Influence of heredity and environment on peak bone density: a parent-offspring study. *J Clin Densitom.* 2010;13(3):301–6. <https://doi.org/10.1016/j.jocd.2010.03.003>.
4. Rondanelli M, Faliva MA, Barrile GC, Cavioni A, Mansueto F, Mazzola G, et al. Nutrition, physical activity, and dietary supplementation to prevent bone mineral density loss: a food pyramid. *Nutrients.* 2022;14(1):74. <https://doi.org/10.3390/nu14010074>.

5. Sambol SZ, Stimac D, Orlić ZC, Guina T. Haematological, biochemical and bone density parameters in vegetarians and non-vegetarians. *West Indian Med J*. 2009;58(6):512–7.
6. Begic Z, Balic D, Rizvanovic M. The association between lipid profile and bone density in postmenopausal women. *Med Arch*. 2012;66(6):378. <https://doi.org/10.5455/medarh.2012.66.378-381>.
7. Brownbill RA, Ilich JZ. Lipid profile and bone paradox: higher serum lipids are associated with higher bone mineral density in postmenopausal women. *J Women's Health (Larchmont, NY)*. 2006;15(3):261.
8. Sprini D, Rini GB, Di Stefano L, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. *Clin Cases Miner Bone Metabol*. 2014;11(2):117–9. <https://doi.org/10.11138/ccmbm/2014.11.2.117>.
9. Alkhenizan A, Mahmoud A, Hussain A, Gabr A, Alsoghayer S, Eldali A. The relationship between 25 (OH) D levels (vitamin D) and bone mineral density (BMD) in a Saudi population in a community-based setting. *PLoS ONE*. 2017;12(1):e169122. <https://doi.org/10.1371/journal.pone.0169122>.
10. Sun J, Zhao M, Hou Y, Zhang C, Oh J, Sun Z, et al. Circulating serum vitamin D levels and total body bone mineral density: a Mendelian randomization study. *J Cell Mol Med*. 2019;23(3):2268–71. <https://doi.org/10.1111/jcmm.14153>.
11. Hu X, Ma S, Yang C, Wang W, Chen L. Relationship between senile osteoporosis and cardiovascular and cerebrovascular diseases. *Exp Ther Med*. 2019;17(6):4417–20. <https://doi.org/10.3892/etm.2019.7518>.
12. D'Amelio P, Pescarmona GP, Gariboldi A, Isaia GC. High density lipoproteins (HDL) in women with postmenopausal osteoporosis: a preliminary study. *Menopause*. 2001;8(6):429–32. <https://doi.org/10.1097/00042192-200111000-00008>.
13. Winzenberg T, Powell S, Shaw KA, Jones G. Effects of vitamin D supplementation on bone density in healthy children: systematic review and meta-analysis. *BMJ (Clin Res ed)*. 2011;342:c7254. <https://doi.org/10.1136/bmj.c7254>.
14. Sertpoyraz FM, Deniz S. Bone mineral density and vitamin D levels in patients with group A COPD. *Aging Male*. 2020;23(5):873–8. <https://doi.org/10.1080/13685538.2019.1612869>.
15. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. *Am J Clin Nutr*. 2004;79(3):362–71. <https://doi.org/10.1093/ajcn/79.3.362>.
16. Leung HH, Galano J, Crauste C, Durand T, Lee JC. Combination of lutein and zeaxanthin, and DHA regulated polyunsaturated fatty acid oxidation in H₂O₂-stressed retinal cells. *Neurochem Res*. 2020;45(5):1007–19. <https://doi.org/10.1007/s11064-020-02994-4>.
17. Maghbooli Z, Khorrani-nezhad L, Adabi E, Ramezani M, Asadollahpour E, Razi F, et al. Negative correlation of high-density lipoprotein-cholesterol and bone mineral density in postmenopausal Iranian women with vitamin D deficiency. *Menopause*. 2018;25(4):458–64. <https://doi.org/10.1097/GME.0000000000001082>.
18. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society. *J Clin Endocrinol Metabol*. 2011;96(7):1911–30. <https://doi.org/10.1210/jc.2011-0385>.
19. Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment. *Int J Mol Sci*. 2018;19(2):360. <https://doi.org/10.3390/ijms19020360>.
20. Paspaliaris V, Kolios G. Stem cells in osteoporosis: from biology to new therapeutic approaches. *Stem Cells Int*. 2019;2019:1–16. <https://doi.org/10.1155/2019/1730978>.
21. Yabing WKS. Research progress in the mechanism of action of transforming growth factor- β in bone metabolism. *Chin J Osteoporos*. 2020;26(02):308–12.
22. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. *Arterioscler Thromb Vasc Biol*. 1997;17(4):680–7.
23. Hsu Y, Venners SA, Terwedow HA, Feng Y, Niu T, Li Z, et al. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. *Am J Clin Nutr*. 2006;83(1):146–54.
24. Kha HT, Basseri B, Shouhed D, Richardson J, Tetradis S, Hahn TJ, et al. Oxysterols regulate differentiation of mesenchymal stem cells: pro-bone and anti-fat. *J Bone Miner Res*. 2004;19(5):830–40. <https://doi.org/10.1359/jbmr.040115>.
25. Dennison EM, Syddall HE, Aihie Sayer A, Martin HJ, Cooper C. Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort Study. *QJM*. 2007;100(5):297–303. <https://doi.org/10.1093/qjmed/hcm023>.
26. Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgensen LN. Effect of combined oral estrogen/progestogen preparation (Kliogest[®]) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve. *Acta Obstet Gynecol Scan*. 2003;82(9):857–66.
27. Mazidi M, Mikhailidis DP, Banach M. Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. *Int J Cardiol*. 2019;276:242–7. <https://doi.org/10.1016/j.ijcard.2018.11.095>.
28. Heikkinen AM, Tuppurainen MT, Niskanen L, Komulainen M, Penttilä I, Saarikoski S. Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. *Eur J Endocrinol*. 1997;137:495–502.
29. Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1 α ,25-dihydroxyvitamin D3 inhibits uncoupling protein 2 expression in human adipocytes. *FASEB J*. 2002;16(13):1–20. <https://doi.org/10.1096/fj.02-0255fj>.
30. Wehmeier K, Beers A, Haas MJ, Wong NCW, Steinmeyer A, Zugel U, et al. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. *Biochem Biophys Acta*. 2005;1737(1):16–26.
31. von Mühlen DG, Greendale GA, Garland CF, Wan L, Barrett-Connor E. Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. *Osteoporos Int*. 2005;16(12):1721–6. <https://doi.org/10.1007/s00198-005-1910-8>.
32. Nadeem SM, Rafique I, Hayder I, Irshad R, Bashir S, Ullah R, et al. Comparison of vitamin D levels with bone density, calcium, phosphate and alkaline phosphatase—an insight from major cities of Pakistan. *J Pak Med Assoc*. 2018;68(4):543–7.
33. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh J, et al. Molecular mechanisms of vitamin D action. *Calcif Tissue Int*. 2013;92(2):77–98. <https://doi.org/10.1007/s00223-012-9619-0>.
34. Buizert PJ, van Schoor NM, Lips P, Deeg DJ, Eekhoff EM. Lipid levels: A link between cardiovascular disease and osteoporosis? *J Bone Miner Res*. 2009;24(6):1103–9. <https://doi.org/10.1359/jbmr.081262>.
35. Jeong I, Cho SW, Kim SW, Choi HJ, Park KS, Kim SY, et al. Lipid profiles and bone mineral density in pre- and postmenopausal women in Korea. *Calcif Tissue Int*. 2010;87(6):507–12. <https://doi.org/10.1007/s00223-010-9427-3>.
36. Adler RA. Update on osteoporosis in men. *Best Pract Res Clin Endocrinol*. 2018;32(5):759–72. <https://doi.org/10.1016/j.beem.2018.05.007>.
37. Briot K, Roux C, Thomas T, Blain H, Buchon D, Chapurlat R, et al. 2018 update of French recommendations on the management of postmenopausal osteoporosis. *Jt Bone Spine*. 2018;85(5):519–30. <https://doi.org/10.1016/j.jbspin.2018.02.009>.
38. Windahl SH, Börjesson AE, Farman HH, Engdahl C, Movérare-Skrtic S, Sjögren K, et al. Estrogen receptor- α in osteocytes is important for trabecular bone formation in male mice. *Proc Natl Acad Sci*. 2013;110(6):2294–9. <https://doi.org/10.1073/pnas.1220811110>.
39. Kun G, Weiji Y, Quan L, Qinong M, Jinlong Y, Jinqun L, et al. Study on the relationship between the ratio of neutrophil to lymphocyte and osteoporosis. *Chin J Osteoporos*. 2019;25(08):1134–7.
40. Wei SZ, Zhifen HZEA. Effects of estrogen on Wnt16, β -catenin, OPG, RANKL expression in bone tissue of ovariectomized rats. *Zhejiang Med*. 2017;39(04):245–9.
41. Schweiger J, Schweiger U, Hüppe M, Kahl K, Greggerson W, Jauch-Chara K, et al. The use of antidepressive agents and bone mineral density in women: a meta-analysis. *Int J Environ Res Public Health*. 2018;15(7):1373. <https://doi.org/10.3390/ijerph15071373>.
42. Sheu Y, Lanteigne A, Stürmer T, Pate V, Azrael D, Miller M. SSRI use and risk of fractures among perimenopausal women without mental disorders. *Injury Prev*. 2015;21(6):397–403. <https://doi.org/10.1136/injuryprev-2014-041483>.
43. Vari R, Scaccocchio B, D'Amore A, Giovannini C, Gessani S, Masella R. Gender-related differences in lifestyle may affect health status. *Annali dell'Istituto superiore di sanita*. 2016;52(2):158–66. https://doi.org/10.4415/ANN_16_02_06.
44. Nieves JW. Sex-differences in skeletal growth and aging. *Curr Osteoporos Rep*. 2017;15(2):70–5. <https://doi.org/10.1007/s11914-017-0349-0>.

45. Niu P, Li H, Liu D, Zhang YF, Liu Y, Liang C. Association between HDL-C and bone mineral density: an cross-sectional analysis. *Int J Gen Med.* 2021;14:8863–72. <https://doi.org/10.2147/IJGM.S334972>.
46. Zolfaroli I, Ortiz E, García-Pérez M, Hidalgo-Mora JJ, Tarín JJ, Cano A. Positive association of high-density lipoprotein cholesterol with lumbar and femoral neck bone mineral density in postmenopausal women. *Maturitas.* 2021;147:41–6. <https://doi.org/10.1016/j.maturitas.2021.03.001>.
47. Zhang Q, Zhou J, Wang Q, Lu C, Xu Y, Cao H, et al. Association between bone mineral density and lipid profile in Chinese women. *Clin Interv Aging.* 2020;15:1649–64. <https://doi.org/10.2147/CIA.S266722>.
48. Bin XGZX. The related research of antero-posterior lumbar spine bone mineral density data of 2 205 healthy men in Shanghai. *J Southeast Univ (Med Sci Ed).* 2016;35(3):301–4.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

